Empowering Lives Through Precision Neurogenetics

At Cognigenics, we are advancing a new class of therapeutics that aims to redefine treatment outcomes for neuropsychiatric disorders. Our siRNA-based therapies, delivered via intranasal lipid nanoparticles, are designed to target the molecular drivers of psychiatric and cognitive symptoms, in order to offer safe, reversible modulation of brain circuits without systemic exposure.

MEASURABLE IMPACT, MEANINGFUL CHANGE

Improved Mental and Emotional Balance

By modulating activity in the interpeduncular–ventral hippocampus pathway, our therapeutics show promise in restoring emotional regulation, enhancing mood, and increasing stress resilience.

Our Goal: A Better Experience for Patients

Noninvasive, At-Home Administration

Our delivery system is designed for simplicity: a once-weekly, self-administered intranasal spray that may reduce the need for daily pills or clinical procedures.

Empowering Patient Control

Ease of use promotes adherence and places therapeutic management back in the hands of the individual.

A Foundation in Science, A Vision for Impact

Third-Party Validation

Our outcomes are validated through studies performed at independent, AAALAC-accredited laboratories utilizing behavioral assays, immunohistochemistry, qPCR, and electrophysiology, and confirmed through peer-reviewed evaluation.

A Platform for Broader Transformation

While we begin with Parkinson’s Disease Psychosis with Anxiety, our AcuGen platform is scalable across cognitive impairment, neurodegeneration, and anxiety spectrum conditions.